CHF 0.0015 after-hours: IGPH.SW IGEA Pharma (SIX) saw 2.03M volume, watch liquidity
IGPH.SW stock fell to CHF 0.0015 in after-hours trade on 15 Jan 2026 after a 25.00% intraday drop and a heavy 2,033,000 share print. Traders pushed liquidity far above the 50-day average volume of 193,941, making IGEA Pharma N.V. (IGPH.SW) one of the most active names on the SIX market after hours. The move reflects thin market depth, negative trailing EPS of -0.03 and a tiny market cap of CHF 505,545.00, all of which shape short-term trading risk and opportunity for speculators and micro-cap investors.
IGPH.SW stock: After-hours price action and volume
IGPH.SW stock closed at CHF 0.0015 after hours on 15 Jan 2026, down 25.00% from the previous close of CHF 0.0020. Volume surged to 2,033,000, more than ten times the average, indicating a liquidity event rather than broad institutional rotation. High intraday volatility is expected for this micro-cap on SIX given the year high of CHF 0.05 and year low of CHF 0.0005.
IGPH.SW stock: Financials and valuation snapshot
IGEA Pharma reports trailing EPS of -0.03 and a negative PE of -0.05, underscoring ongoing losses and no earnings coverage. The company shows a low cash per share and negative book value per share, with shareholders’ equity per share at -0.00683. Market cap sits at CHF 505,545.00, and shares outstanding are 337,030,016, which amplifies dilution risk for any capital raise.
IGPH.SW stock: Technicals, liquidity and trading signals
Price averages are weak: the 50-day average is CHF 0.00214 and the 200-day average is CHF 0.00517, both well above the current price. The stock’s relative volume is 10.48, signaling a rare surge of attention. For traders, the key levels are day high CHF 0.002 and day low CHF 0.0015; a break above CHF 0.0030 on sustained volume would reduce immediate downside risk.
IGPH.SW stock: Meyka grade and model forecast
Meyka AI rates IGPH.SW with a score out of 100: 58.71 (C+) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a target near CHF 0.00517 over a 12-month horizon, implying an upside of about 244.67% from the current CHF 0.0015. Forecasts are model-based projections and not guarantees.
IGPH.SW stock: Risks, catalysts and sector context
IGEA Pharma sits in Healthcare, Medical – Diagnostics & Research, where peers trade at much higher valuations: sector average PE is 33.43. Main risks are continued negative earnings, low liquidity, and potential dilution. Catalysts include regulatory approvals for products like Alz1, new commercial partnerships, or a capital raise that reduces short-term cash pressure.
IGPH.SW stock: Price targets and analyst-style outlook
Near-term traders may use a conservative recovery target of CHF 0.00300 and a 12-month target aligned with the 200-day average at CHF 0.00517. A bullish scenario tied to successful product uptake could justify a stretch target of CHF 0.02000, but that requires material positive news and financing clarity. These targets reflect scenario planning, not firm recommendations.
Final Thoughts
IGPH.SW stock is trading as a highly speculative micro-cap on the SIX market after hours at CHF 0.0015 with 2,033,000 shares traded on 15 Jan 2026. The short-term thesis centers on liquidity-driven moves and low float dynamics rather than stable fundamentals. Financials show negative EPS of -0.03, negative book value per share, and a market cap of CHF 505,545.00, which raises capital-raising and dilution risk. Meyka AI rates the stock 58.71 (C+) — HOLD, and our scenario targets place a near-term level at CHF 0.00300 and a 12-month model target at CHF 0.00517, implying model-based upside of about 244.67% from current levels. Traders should prioritise volume confirmation and clear corporate updates before increasing exposure. For more company detail visit the IGEA Pharma website and our platform page for IGPH.SW at Meyka stock page. Forecasts are model-based projections and not guarantees, and this analysis is informational, not investment advice.
FAQs
What drove the after-hours move in IGPH.SW stock?
The after-hours move to CHF 0.0015 on 15 Jan 2026 was driven by a volume spike of 2,033,000 shares. This surge reflects low float volatility and liquidity trading rather than confirmed company fundamentals or new earnings.
What is Meyka AI’s forecast for IGPH.SW stock?
Meyka AI’s forecast model projects a 12-month target near CHF 0.00517, implying about 244.67% upside from CHF 0.0015. Forecasts are model-based projections and not guarantees.
How risky is investing in IGPH.SW stock?
IGPH.SW stock is high risk due to negative EPS (-0.03), tiny market cap (CHF 505,545.00), negative book value, and historically wide price swings. Liquidity events can cause sharp moves in either direction.
Where can I find official company information for IGPH.SW?
Official company information and filings are available on the IGEA Pharma website at IGEA Pharma. For market data and Meyka insights see our IGPH.SW stock page at Meyka stock page.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
